nach oben

Der Schmerz

Erschienen in:

17.01.2022 | Prophylaxe | CME

CGRP-Antikörper in der Migräneprophylaxe

Der neue Standard in der Migränetherapie?

verfasst von: Till Hamann, Florian Rimmele, Tim Patrick Jürgens

Erschienen in: Der Schmerz | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Migräne geht mit einem starken individuellen Leidensdruck einher, weshalb einer effektiven prophylaktischen Behandlung hohe Bedeutung zukommt. Das Spektrum klassischer Prophylaktika wird nun durch monoklonale Antikörper gegen das „calcitonin gene-related peptide“ (CGRP) und dessen Rezeptor erweitert. Die Antikörper wiesen in den Zulassungsstudien eine zuverlässige Wirksamkeit gegenüber Placebo und einen raschen Wirkeintritt bei niedriger Nebenwirkungsrate und vernachlässigbaren Interaktionen auf. Zudem wurde in zahlreichen Studien unter anderem eine Wirkung der Antikörper auch bei therapierefraktärer Migräne nachgewiesen. Umfassende direkte Vergleiche der Antikörper untereinander und mit den bisher etablierten Medikamenten gibt es noch nicht. Erste Studien legen aber eine bessere Verträglichkeit und Wirksamkeit gegenüber etablierten Medikamenten oder anderen Antikörpern nahe. Die Rolle der Antikörper in den etablierten Therapiekaskaden bleibt zu klären.

Göbel H (2012) Migräne. In: Erfolgreich gegen Kopfschmerzen und Migräne. Springer, Berlin, Heidelberg, S 55–232

Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56 PubMed

Lassen LH, Ashina M (1997) Nitric oxide synthase inhibition in migraine. Lancet 349:401–402 PubMed

Jonas V, Lin CR, Kawashima E, Semon D, Swanson LW, Mermod JJ, Evans RM, Rosenfeld MG (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240–244 PubMed

Juaneda C, Dumont Y, Quirion R (2000) The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci 21:432–438 PubMed

Sternini C (1992) Enteric and visceral afferent CGRP neurons: targets of innervation and differential expression patterns. Ann NY Acad Sci 657:170–186 PubMed

Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR (2004) Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 500(1-3):315–330 PubMed

Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17:533–585 PubMed

Edvinsson L, Ekman R, Jansen I, McCulloch J, Uddman R (1987) Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 7:720–728 PubMed

10.

Amara SG, Arriza JL, Leff SE, Swanson LW, Evans RM, Rosenfeld MG (1985) Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229:1094–1097 PubMed

11.

Jansen-Olesen I, Mortensen A, Edvinsson L (1996) Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16:310–316 PubMed

12.

Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, Durham PL (2007) Neuron–glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47:1008–1023 PubMedPubMedCentral

13.

Vause CV, Durham PL (2009) CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem 110:811–821 PubMedPubMedCentral

14.

Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, Waldvogel HJ, Jamaluddin MA, Russo AF, Hay DL (2015) A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2(6):595–608 PubMedPubMedCentral

15.

Russo AF (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 55:533–552 PubMed

16.

Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, de Boer I, Guglielmetti M et al (2019) CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain 20:27. https://doi.org/10.1186/s10194-019-0979-y CrossRefPubMedPubMedCentral

17.

Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine—current understanding and treatment. N Engl J Med 346:257–270 PubMed

18.

Limmroth V (2002) How do sumatriptan and co. work? The action mechanisms of triptans. Pharm Unserer Zeit 31:458 PubMed

19.

Pervez H, Khemani L, Khan MA, Seedat AM, Roshan F (2020) Calcitonin gene-related peptide antagonists as a savior in episodic and chronic migraine: a review. Cureus 12(6):e8711 PubMedPubMedCentral

20.

Diener H‑C, Förderreuther S, Gaul C, Giese F, Hamann T, Holle-Lee D, Jürgens TP, Kamm K, Kraya T, Lampl C (2020) Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor, Ergänzung der S1-Leitlinie Therapie der Migräneattacke und Prophylaxe der Migräne. DGNeurologie 3:124–128

21.

Diener H‑C, May A et al (2019) Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor, Ergänzung der S1-Leitlinie Therapie der Migräneattacke und Prophylaxe der Migräne. Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie, (Online: www.dgn.org/leitlinien)

22.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123–2132 PubMed

23.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026–1037 PubMed

24.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319:1999–2008 PubMed

25.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE‑1 randomized clinical trial. JAMA Neurol 75(9):1080–1088 PubMedPubMedCentral

26.

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE‑2 phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442–1454 PubMed

27.

Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241–254 PubMedPubMedCentral

28.

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434 PubMed

29.

Detke HC, Goadsby PJ, Shufang W, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211–e2221 PubMedPubMedCentral

30.

Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE‑2. Neurology 94:e1365–e1377 PubMedPubMedCentral

31.

Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:e2309–e2320 PubMedPubMedCentral

32.

Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM (2021) Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41:340–352 PubMed

33.

Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE‑2. Headache 61(1):125–136 PubMed

34.

Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114 PubMedPubMedCentral

35.

Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d’Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35 PubMedPubMedCentral

36.

Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814–825. https://doi.org/10.1016/S1474-4422(20)30279-9 CrossRefPubMed

37.

Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030–1040 PubMed

38.

Reuter U, Goadsby PJ, Lanteri-Minet M, Shihua W, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280–2287 PubMed

39.

Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40(6):543–553 PubMed

40.

Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6 PubMedPubMedCentral

41.

Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F, Sacco S (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20:99 PubMedPubMedCentral

42.

DMKG (2018) Informationen der DMKG zum Einsatz monoklonaler Antikörper in der Migräneprophylaxe

43.

Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G, Boudreau GP, McAllister P, Vu T, Zhang F, Cheng S, Picard H, Wen S, Kahn J, Klatt J, Mikol D (2018) Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 19(1):92 PubMedPubMedCentral

44.

Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E (2021) Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain 22:15 PubMedPubMedCentral

45.

Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y (2019) Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache 59(10):1743–1752 PubMed

46.

Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R (2021) Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA 325(23):2348–2356 PubMed

47.

Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gandolla A, Raffaelli B, Reuter U, Neeb L (2021) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. J Headache Pain 22(Suppl 1):P328 (The International Headache Congress—IHS and EHF Joint Congress 2021)

48.

Morollón N, Belvís R, De Dios A, Pagès A, Massip M (2021) What if a monoclonal antibody doesn’t work as a migraine preventive treatment? Description of the experience in switching between monoclonals antibodies in a Headache Unit. J Headache Pain 22(Suppl 1):P291 (The International Headache Congress—IHS and EHF Joint Congress 2021)

49.

Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. https://doi.org/10.1177/03331024211046617 CrossRefPubMedPubMedCentral

50.

Stauffer VL, Shufang W, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK (2019) Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. Headache 59:834–847 PubMedPubMedCentral

51.

Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Reuter U (2021) Migraine evolution after discontinuation of preventive treatment with CGPR-(receptor) antibodies: a prospective, longitudinal study. J Headache Pain 22(Suppl 1):P287 (The International Headache Congress—IHS and EHF Joint Congress 2021)

52.

Vaghi G, Bitetto V, Guaschino E, De Icco R, Ghiotto N, Tassorelli C, Sances G (2021) Does erenumab suspension affect chronic migraine course? A real life experience. J Headache Pain 22(Suppl 1):P302 (The International Headache Congress—IHS and EHF Joint Congress 2021)

53.

Melo-Carrillo A, Strassman AM, Schain AJ, Manack Adams A, Brin MF, Burstein R (2021) Combined onabotulinumtoxin A/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons. Cephalalgia 41:17–32 PubMed

54.

Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxin A: a retrospective chart review. Pain Ther 10(2):809–826 PubMedPubMedCentral

55.

Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Campos VR, Seminerio MJ, Krasenbaum LJ, Shen H, Stratton J (2021) Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain 22(1):3 PubMedPubMedCentral

56.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5‑year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716–1725 PubMedPubMedCentral

57.

Rosen N, Pearlman E, Ruff D, Day K, Nagy AJ (2018) 100 % response rate to galcanezumab in patients with episodic migraine: a post hoc analysis of the results from phase 3, randomized, double-blind, placebo-controlled EVOLVE‑1 and EVOLVE-2 studies. Headache 58:1347–1357 PubMedPubMedCentral

58.

González-Quintanilla V, Pérez-Pereda S, González-Suárez A, Madera J, Toriello M, Pascual J (2021) Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: a report of two cases. Cephalalgia 41(11-12):1272–1275 PubMed

59.

Hamann T, Kamm K, Kropp P, Rimmele F, Jürgens TP (2020) Migräneprophylaxe – alles nur noch Antikörper? Schmerz 34:476–485. https://doi.org/10.1007/s00482-020-00500-x CrossRefPubMed

60.

Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L, Pittelkow MR, Mangold AR (2021) Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open 4(4):e217934 PubMedPubMedCentral

61.

Greene KA, Gentile CP, Szperka CL, Yonker M, Gelfand AA, Grimes B, Irwin SL (2021) Calcitonin gene-related peptide monoclonal antibody use for the preventive treatment of refractory headache disorders in adolescents. Pediatr Neurol 114:62–67 PubMed

62.

Noseda R, Bedussi F, Gobbi C, Zecca C, Ceschi A (2021) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia 41:789–798 PubMed

63.

Frank F, Ulmer H, Sidoroff V, Broessner G (2021) CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis. Cephalalgia 41(11-12):1222–1239 PubMedPubMedCentral

64.

Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, Hours-Zesiger P, Nickisch J, Sieder C, Hentschke C, Maier-Peuschel M (2021) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. https://doi.org/10.1177/03331024211053571 CrossRefPubMedPubMedCentral

65.

Novartis (2020) Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention. Novartis, Basel

Titel: CGRP-Antikörper in der Migräneprophylaxe
Der neue Standard in der Migränetherapie?
verfasst von: Till Hamann
Florian Rimmele
Tim Patrick Jürgens
Publikationsdatum: 17.01.2022
Verlag: Springer Medizin
Schlagwörter: Prophylaxe
Migräne
Erenumab
Galcanezumab
Fremanezumab
Erschienen in: Der Schmerz / Ausgabe 1/2022
Print ISSN: 0932-433X
Elektronische ISSN: 1432-2129
DOI: https://doi.org/10.1007/s00482-021-00613-x

Neu in den Fachgebieten Neurologie und Psychiatrie

19.03.2023 | Demenz anderer Ursache | Nachrichten

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

CGRP-Antikörper in der Migräneprophylaxe

Der neue Standard in der Migränetherapie?

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Nur der Torwart muss die Demenz nicht fürchten

Epidurale Stimulation stärkt Feinmotorik nach Schlaganfall

Jugendliche Gewaltopfer besonders suizidgefährdet

Kein gesteigertes Suizidrisiko bei Personen mit HPV-positiven Tumoren

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Effektivität einer individualisierten, multimodalen Behandlung bei chronischen Schmerzpatienten

Herausforderungen der Schmerzerfassung und -therapie bei Personen mit Intelligenzminderung und Entwicklungsstörungen

Erratum zu: Die Schmerzasymbolie – um 1930 von Paul F. Schilder entdeckt und heute fast vergessen?

President´s Corner (Mitteilungen der Deutschen Schmerzgesellschaft e.V.)

Elterliche Reaktionen auf kindliche Schmerzen

Wahrnehmungen zum Umgang mit Opioiden bei COVID-19

Neu in den Fachgebieten Neurologie und Psychiatrie

Nur der Torwart muss die Demenz nicht fürchten

Epidurale Stimulation stärkt Feinmotorik nach Schlaganfall

Jugendliche Gewaltopfer besonders suizidgefährdet

Kein gesteigertes Suizidrisiko bei Personen mit HPV-positiven Tumoren